R. Sehn, L. Donaldson, J. Chhanabhai, M. Fitzgerald, C. Gill et al., Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia, Journal of Clinical Oncology, vol.23, issue.22, pp.5027-5033, 2005.
DOI : 10.1200/JCO.2005.09.137

B. Coiffier, C. Thieblemont, E. Van-den-neste, G. Lepeu, I. Plantier et al., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe, pp.2040-2045, 2010.

S. Barrington, N. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings et al., Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-3058, 2014.
DOI : 10.1200/JCO.2013.53.5229

M. Juweid, G. Wiseman, J. Vose, J. Ritchie, Y. Menda et al., Response Assessment of Aggressive Non-Hodgkin???s Lymphoma by Integrated International Workshop Criteria and Fluorine-18???Fluorodeoxyglucose Positron Emission Tomography, Journal of Clinical Oncology, vol.23, issue.21, pp.4652-4661, 2005.
DOI : 10.1200/JCO.2005.01.891

C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani et al., Meignan M: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large Bcell lymphoma: SUV-based assessment versus visual analysis Journal of nuclear medicine : official publication, Society of Nuclear Medicine, pp.1626-1632, 2007.

E. Itti, M. Meignan, A. Berriolo-riedinger, A. Biggi, A. Cashen et al., An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax. European journal of nuclear medicine and molecular imaging, pp.1312-1320, 2013.

M. Sasanelli, M. Meignan, C. Haioun, A. Berriolo-riedinger, R. Casasnovas et al., Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. European journal of nuclear medicine and molecular imaging, pp.2017-2022, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01141151

H. Lanic, S. Mareschal, F. Mechken, J. Picquenot, M. Cornic et al., Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.116, issue.1, pp.34-42, 2012.
DOI : 10.1200/JCO.2010.30.0368

URL : https://hal.archives-ouvertes.fr/hal-00673375

S. Swerdlow, . Ce, and N. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008.

A. Alizadeh, M. Eisen, R. Davis, C. Ma, I. Lossos et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.303, issue.6769, pp.503-511, 2000.
DOI : 10.1038/35000501

A. Rosenwald, G. Wright, W. Chan, J. Connors, E. Campo et al., The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.25, pp.1937-1947, 2002.
DOI : 10.1056/NEJMoa012914

G. Wright, B. Tan, A. Rosenwald, E. Hurt, A. Wiestner et al., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.9991-9996, 2003.
DOI : 10.1073/pnas.1732008100

S. Mareschal, P. Ruminy, C. Bagacean, V. Marchand, M. Cornic et al., Accurate Classification of Germinal Center B-Cell???Like/Activated B-Cell???Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase???Multiplex Ligation-Dependent Probe Amplification Assay, The Journal of Molecular Diagnostics, vol.17, issue.3, 2015.
DOI : 10.1016/j.jmoldx.2015.01.007

URL : https://hal.archives-ouvertes.fr/hal-01145953

G. Lenz and L. Staudt, Aggressive lymphomas, pp.1417-1429, 2010.

D. Cunningham, E. Hawkes, A. Jack, W. Qian, P. Smith et al., Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles, The Lancet, vol.381, issue.9880, pp.1817-1826, 2013.
DOI : 10.1016/S0140-6736(13)60313-X

J. Jais, C. Haioun, T. Molina, D. Rickman, A. De-reynies et al., The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab, Leukemia, vol.65, issue.10, pp.1917-1924, 2008.
DOI : 10.1086/444428

URL : https://hal.archives-ouvertes.fr/inserm-00339565

G. Lenz, G. Wright, S. Dave, X. W. Powell, J. Zhao et al., Stromal Gene Signatures in Large-B-Cell Lymphomas, New England Journal of Medicine, vol.359, issue.22, pp.2313-2323, 2008.
DOI : 10.1056/NEJMoa0802885

C. Hans, D. Weisenburger, T. Greiner, R. Gascoyne, J. Delabie et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-282, 2004.
DOI : 10.1182/blood-2003-05-1545

N. Rayman, K. Lam, B. Van-der-holt, C. Koss, D. Veldhuizen et al., Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.1, pp.23-32, 2011.
DOI : 10.3816/CLML.2011.n.003

G. Gutierrez-garcia, T. Cardesa-salzmann, F. Climent, E. Gonzalez-barca, S. Mercadal et al., Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Blood, vol.117, issue.18, pp.4836-4843, 2011.
DOI : 10.1182/blood-2010-12-322362

K. Gu, D. Weisenburger, K. Fu, W. Chan, T. Greiner et al., Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation, Hematological Oncology, vol.28, issue.27, pp.143-149, 2012.
DOI : 10.1002/hon.1017

C. Thieblemont, J. Briere, N. Mounier, H. Voelker, W. Cuccuini et al., The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study, Journal of Clinical Oncology, vol.29, issue.31, pp.4079-4087, 2011.
DOI : 10.1200/JCO.2011.35.4423

H. Lanic, R. Boellaard, O. Doherty, M. Weber, W. Mottaghy et al., Valeur pronostique du profil d'expression génique et du PET SCAN dans les lymphomes diffus à grandes cellules de phénotype B. Thèse d'exercice pour le diplome d'état en médecine-Faculté de médecine de Rouen EANM procedure guidelines for tumour PET imaging: version 1.0. European journal of nuclear medicine and molecular imaging, pp.181-200, 2010.

M. Meignan, M. Sasanelli, R. Casasnovas, S. Luminari, F. Fioroni et al., Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European journal of nuclear medicine and molecular imaging, pp.1113-1122, 2014.

A. Cottereau, . Bs, . Broussais, O. Casasnovas, S. Kanoun et al., Pronostic value of Baseline Metabolic Tumor Volume (MTV0) measured on FDG PET/CT in patients with peripheral T-cell Lymphoma (PTCL), 13-ICML Oral Presentations Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma, European journal of nuclear medicine and molecular imaging 2014, pp.100-1801735, 2015.

J. Spinelli and J. Sutherland, Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, pp.5027-5033, 2005.

M. Macro and C. Sebban, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the

B. Woda, R. Fisher, B. Peterson, and S. Horning, Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.24, pp.3121-3127, 2006.

G. Salles and P. Gaulard, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, The New England journal of medicine, vol.346, pp.235-242, 2002.

S. Barrington, N. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings et al., Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-3058, 2014.
DOI : 10.1200/JCO.2013.53.5229

M. Weckesser, A. Franzke, F. Bengel, J. Dürig, J. Matschke et al., Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas ? a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial), p.391, 2014.

E. Rohren, N. Blumstein, and A. Stolpen, Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, pp.4652-4661, 2005.

F. Boesen and A. , FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, vol.107, pp.52-59, 2006.

N. Mikhaeel, M. Hutchings, P. Fields, O. Doherty, M. Timothy et al., FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, pp.1514-1523, 2005.

B. Siegel, A. Cashen, and P. Vera, Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. European journal of nuclear medicine and molecular imaging, pp.2017-2022, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01141151

M. Song, J. Chung, H. Shin, S. Lee, S. Lee et al., Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement, Annals of Hematology, vol.74, issue.5, pp.697-703, 2012.
DOI : 10.1007/s00277-011-1357-2

X. Yu, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, pp.503-511, 2000.

H. Hermelink, E. Smeland, and J. Giltnane, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, The New England journal of medicine, vol.346, pp.1937-1947, 2002.

G. Lenz, G. Wright, S. Dave, X. W. Powell, J. Zhao et al., Stromal Gene Signatures in Large-B-Cell Lymphomas, New England Journal of Medicine, vol.359, issue.22, pp.2313-2323, 2008.
DOI : 10.1056/NEJMoa0802885

F. Bohers, E. Stamatoullas, and A. , Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma, Leukemia & lymphoma, vol.53, pp.34-42, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00673375

G. Wright, B. Tan, A. Rosenwald, E. Hurt, A. Wiestner et al., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.9991-9996, 2003.
DOI : 10.1073/pnas.1732008100

P. Gobbi, F. Merli, and A. Versari, Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European journal of nuclear medicine and molecular imaging, 2014.

E. Ferrant, F. Brunotte, and R. Casasnovas, Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging, pp.1735-1743, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00998569

A. Hagenbeek and E. Zucca, Revised response criteria for malignant lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.25, pp.579-586, 2007.

J. Kotzerke, O. Hoekstra, and J. Pruim, EANM procedure guidelines for tumour PET imaging: version 1.0. European journal of nuclear medicine and molecular imaging, pp.181-200, 2010.

P. Gobbi, F. Merli, and A. Versari, Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European journal of nuclear medicine and molecular imaging, pp.1113-1122, 2014.

T. Kim, J. Paeng, I. Chun, B. Keam, Y. Jeon et al., Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma, Cancer, vol.37, issue.6, pp.1195-1202, 2013.
DOI : 10.1002/cncr.27855

J. Sancho, L. Arenillas, S. Serrano, and L. Escoda, Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Blood, vol.117, pp.4836-4843, 2011.

R. Delwel and D. De-jong, Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials, Clinical lymphoma, myeloma & leukemia, vol.11, pp.23-32, 2011.

K. Gu, D. Weisenburger, K. Fu, W. Chan, T. Greiner et al., Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation, Hematological Oncology, vol.28, issue.27, pp.143-149, 2012.
DOI : 10.1002/hon.1017

A. Sundstrom, C. Cogliatti, and S. , The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.29, pp.4079-4087, 2011.

J. Read, J. Koff, L. Nastoupil, J. Williams, J. Cohen et al., Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms, Clinical Lymphoma Myeloma and Leukemia, vol.14, issue.6, pp.460-467, 2014.
DOI : 10.1016/j.clml.2014.05.002

T. Molina and T. Fest, Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation- Dependent Probe Amplification Assay: A CALYM Study. The Journal of molecular diagnostics : JMD 2015, Scott DW, vol.29
URL : https://hal.archives-ouvertes.fr/hal-01145953

W. Connors and J. , Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue, Blood, vol.123, pp.1214-1217, 2014.

G. Ott, A. Rosenwald, and E. Campo, Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification, Blood, vol.122, issue.24, pp.3884-3891, 2013.
DOI : 10.1182/blood-2013-05-498329

J. Connors and G. Byrne, Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP, Blood, vol.111, pp.5509-5514, 2008.

B. Seligmann and R. Braziel, Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP, Blood, vol.112, pp.3425-3433, 2008.

J. Walewski, M. André, W. Peter, M. Johnson, M. Pfreundschuh et al., on behalf of the ESMO Guidelines Committee: Diffuse Large B-cell non-Hodgkin's lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2015.

N. Mikhaeel, . Sd, . Philipsmm, J. Dunn, P. Fields et al., Does quantitative PET-CT predict prognosis in diffuse large B cell lymphoma, Hematological oncology, issue.1, pp.3196-150, 2013.